Phase IV

Ipsen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

USP Workshop 2021

Participation Not Confirmed

Update your events

New Analyses of Pivotal Phase III Trial Data Highlight Long Duration of Response for Dysport® in Five Therapeutic Indications

Lead Product(s): Botulinum toxin type A

Therapeutic Area: Neurology Product Name: Dysport

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 15, 2021

Details:

Analyses of pivotal study data of Dysport® reveal a large proportion of study patients did not require retreatment for at least 12 weeks (and at least 16 weeks for pediatric upper limb spasticity).

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

USP Workshop 2021

Participation Not Confirmed

Update your events

Novartis' Phase IV Study Showed Superior Tolerability and Efficacy of Aimovig® Compared to Topiramate in Migraine Prevention

Lead Product(s): Erenumab

Therapeutic Area: Neurology Product Name: Aimovig

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: Amgen Inc

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 02, 2020

Details:

The first randomized, double blind, head-to-head study of Aimovig® (erenumab) against topiramate in patients with episodic and chronic migraine (HER-MES) achieved superiority in its primary and secondary endpoints.